NVTA NVTA インビティ

 NVTAのチャート


 NVTAの企業情報

symbol NVTA
会社名 Invitae Corp (NVTA インビティ)
分野(sector)   
産業(industry)   
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 インビタエ(Invitae Corporation)はデオキシリボ核酸(DNA)含有試料を処理し、患者固有の遺伝子変異に関する情報を分析し、臨床医およびその患者向けの試験報告書を生成するための、実験室プロセス、ソフトウェアツールおよび情報科学機能の統合ポートフォリオを利用する。同社の製品は、遺伝性がん、神経障害、心血管障害、小児障害およびその他の遺伝病を含む複数の適応症に使用できる1100以上の遺伝子を含むアッセイで構成される。同社はがん、心臓病、神経筋、小児および希少疾患における遺伝的条件についてパネルを提供する。同社は遺伝子検査、ゲノムネットワーク、ゲノム管理に重点を置く。同社は全ての試験の標準として完全な遺伝子シークエンシングおよび欠失・複製分析を提供している。同社は患者中心のデータ会社であるAltaVoiceに持分を有する。  インビティは、米国の遺伝子診断サ―ビス会社。病院や診療所などの医療機関に、遺伝子診断サ―ビスを提供する。遺伝性の乳がん、腸がん、前立腺がんなどの診断を目的とした遺伝子検査サ―ビスのほか、消費者向け遺伝子検査キットの開発・製造・販売も行う。本社は、カリフォルニア州サンフランシスコ。  itae Corporation is a leading medical genetics company whose mission is to bring comprehensive genetic information into mainstream medicine to improve healthcare for billions of people. Invitae's goal is to aggregate the world's genetic tests into a single service with higher quality, faster turnaround time, and lower prices.
本社所在地 415 374-7782
代表者氏名 Randal W. Scott
代表者役職名 Executive Chairman of the Board
電話番号 +1 415-374-7782
設立年月日 40179
市場名 NYSE(ニューヨーク証券取引所)
ipoyear
従業員数 788人
url www.invitae.com
nasdaq_url
adr_tso
EBITDA EBITDA(百万ドル) -109.05700
終値(lastsale)
時価総額(marketcap)
時価総額 時価総額(百万ドル) 1978.53800
売上高 売上高(百万ドル) 147.69900
企業価値(EV) 企業価値(EV)(百万ドル) 1930.44200
当期純利益 当期純利益(百万ドル) -129.35500
決算概要 決算概要 BRIEF: For the fiscal year ended 31 December 2018 InVitae Corp revenues increased from $68.2M to $147.7M. Net loss before extraordinary items increased 73% to $129.4M. Revenues reflect United States segment increase from $62.4M to $138.2M Rest of World segment increase from $2.5M to $5.3M. Higher net loss reflects Selling and Marketing - Balancing value increase of 41% to $69.5M (expense).

 NVTAのテクニカル分析


 NVTAのニュース

   Profit Investment Management, LLC Buys Eagle Bancorp Inc, Invitae Corp, Under Armour Inc, Sells ...  2021/10/08 14:38:12 GuruFocus
Related Stocks: EGBN , NVTA , UA , RLJ , GBT , GBL ,
   New Study Highlights the Value of Genetic Testing to Guide Clinical Management and Improve Outcomes for Epilepsy Patients  2021/09/25 16:15:00 Benzinga
SAN FRANCISCO , Sept. 25, 2021 /PRNewswire/ -- Invitae (NYSE: NVTA ), a leading medical genetics company, today presented research demonstrating that genetic findings informed clinical management changes that led to improved seizure control and outcomes in the majority of epilepsy patients with actionable findings. This study underscores the importance of genetic testing for all people with epilepsy and supports the growing evidence that medical genetic testing can improve health outcomes and reduce healthcare costs. The findings were presented at the National Society of Genetic Counselors 40th Annual Conference. www.invitae.com (PRNewsFoto/Invitae Corporation)" alt="Invitae''s (NVTA) mission is to bring comprehensive genetic information into mainstream medical practice to improve the quality of healthcare for billions of people. www.invitae.com (PRNewsFoto/Invitae Corporation)"> "Epilepsy impacts the lives of approximately 50 million people worldwide and our findings further demonstrate the value of genetic testing to drive precision treatment decisions for these patients," said lead study author, Dee McKnight , PhD, FACMG. "These results build on the growing evidence that genetic testing at the first presentation with epilepsy can be a key part of an accurate diagnosis and can play an important role in its initial treatment and ongoing management,
   Invitae (NVTA) Presents At Ciitizen Announcement Conference Call Presentation - Slideshow  2021/09/20 16:44:34 Seeking Alpha
   Invitae Corporation (NVTA) Presents at Morgan Stanley 19th Annual Global Healthcare Conference (Transcript)  2021/09/14 19:34:07 Seeking Alpha
   As Invitae pays $325 million to buy Ciitizen, should you invest in NVTA shares?  2021/09/07 19:28:44 Invezz
On Tuesday, Invitae Corp (NYSE:NVTA) shares edged slightly lower after announcing the purchase of health tech company Ciitizen in a cash and stock deal worth $325 million. The company will pay $125 million in cash and issue 7.07 million shares of common stock. It will also issue an additional $225 million in restricted stock units [] The post As Invitae pays $325 million to buy Ciitizen, should you invest in NVTA shares? appeared first on Invezz.
   New Study Highlights the Value of Genetic Testing to Guide Clinical Management and Improve Outcomes for Epilepsy Patients  2021/09/25 16:15:00 Benzinga
SAN FRANCISCO , Sept. 25, 2021 /PRNewswire/ -- Invitae (NYSE: NVTA ), a leading medical genetics company, today presented research demonstrating that genetic findings informed clinical management changes that led to improved seizure control and outcomes in the majority of epilepsy patients with actionable findings. This study underscores the importance of genetic testing for all people with epilepsy and supports the growing evidence that medical genetic testing can improve health outcomes and reduce healthcare costs. The findings were presented at the National Society of Genetic Counselors 40th Annual Conference. www.invitae.com (PRNewsFoto/Invitae Corporation)" alt="Invitae''s (NVTA) mission is to bring comprehensive genetic information into mainstream medical practice to improve the quality of healthcare for billions of people. www.invitae.com (PRNewsFoto/Invitae Corporation)"> "Epilepsy impacts the lives of approximately 50 million people worldwide and our findings further demonstrate the value of genetic testing to drive precision treatment decisions for these patients," said lead study author, Dee McKnight , PhD, FACMG. "These results build on the growing evidence that genetic testing at the first presentation with epilepsy can be a key part of an accurate diagnosis and can play an important role in its initial treatment and ongoing management,
   Invitae (NVTA) Presents At Ciitizen Announcement Conference Call Presentation - Slideshow  2021/09/20 16:44:34 Seeking Alpha
   Invitae Corporation (NVTA) Presents at Morgan Stanley 19th Annual Global Healthcare Conference (Transcript)  2021/09/14 19:34:07 Seeking Alpha
   As Invitae pays $325 million to buy Ciitizen, should you invest in NVTA shares?  2021/09/07 19:28:44 Invezz
On Tuesday, Invitae Corp (NYSE:NVTA) shares edged slightly lower after announcing the purchase of health tech company Ciitizen in a cash and stock deal worth $325 million. The company will pay $125 million in cash and issue 7.07 million shares of common stock. It will also issue an additional $225 million in restricted stock units [] The post As Invitae pays $325 million to buy Ciitizen, should you invest in NVTA shares? appeared first on Invezz.
   As Invitae pays $325 million to buy Ciitizen, should you invest in NVTA shares?  2021/09/07 19:28:44 Invezz
On Tuesday, Invitae Corp (NYSE:NVTA) shares edged slightly lower after announcing the purchase of health tech company Ciitizen in a cash and stock deal worth $325 million. The company will pay $125 million in cash and issue 7.07 million shares of common stock. It will also issue an additional $225 million in restricted stock units [] The post As Invitae pays $325 million to buy Ciitizen, should you invest in NVTA shares? appeared first on Invezz .
   Integrated Investment Consultants, LLC Buys SmileDirectClub Inc, iShares Core S&P 500 ETF, ...  2021/07/21 22:38:08 GuruFocus
Related Stocks: SDC , IVV , VONG , BSV , VOO , SCHD , XSOE , DOCN , GSK , FREL , JKH , SE , IAU , NVTA , BKNG , IAC , IGIB , MGNI ,
   Pacific Biosciences and Invitae Announce Intent to Expand Collaboration  2021/07/20 11:02:00 Intrado Digital Media
Collaboration to develop production-scale HiFi Sequencing platform expected to Include technology from Omniome, Inc.
   Bull of the Day: Exact Sciences (EXAS) | Investing.com  2021/07/19 11:20:06 Investing.com
Stocks Analysis by Zacks Investment Research covering: EXACT Sciences Corporation, Pacific Biosciences of California, InVitae Corp, Natera Inc. Read Zacks Investment Research''s latest article on Investing.com
   Vigilare Wealth Management Buys iShares Core Conservative Allocation ETF, iShares Russell 2000 ...  2021/07/16 12:38:04 GuruFocus
Related Stocks: AOK , IWM , F , GLD , BA , WMT , QCLN , SNOW , NVTA , DKNG , XLE , VGK , PBW , BND , AGG , USMV , KRE , AMT , SOLY , IAU , T , PENN , MPW , CCIV ,
   Prenatal Testing & Newborn Screening Market Research Report 2021 - ResearchAndMarkets.com  2021/07/16 11:35:00 Business Wire
DUBLIN--(BUSINESS WIRE)--The "Prenatal Testing & Newborn Screening Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com''s offering. The market is expected to reach $8.018 billion in 2025 at a CAGR of 14%. Major players in the prenatal testing and newborn screening tests market are PerkinElmer, Progenity, Laboratory Corporation of America Holdings (Sequenom), Natera, Invitae, Centogene, Cradle Genomics, Roche Diagnostics, Quest Diagno

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 NVTA インビティ NVTA )

 twitter  (公式ツイッターやCEOツイッターなど)